

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

June 22, 2018

Department of Corporate Services Bombay Stock Exchange, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE Scrip Code – 506690

Dear Sir,

Re: Our Letter dated June 20, 2018

In continuation of our letter dated June 20, 2018 we wish to clarify that the Company filed an Abbreviated New Drug Application (ANDA) with Para IV certification for generic tadalafil with the USFDA. Pursuant to the said filing Eli Lilly & Company and the ICOS Corporation filed an infringement suit against the Company in the United States District Court for the District of New Jersey seeking to prevent the Company from launching its generic tadalafil in the United States of America. The Parties then mutually negotiated a settlement of the action under which Unichem may launch its generic tadalafil in the United States on or not before March 26, 2019. No other claims have been filed against the Company.

In terms of the settlement, the Company shall pay to Eli Lilly, a royalty of 5% (five per cent) on net sales of the product up till the expiry of the US patent 6943166, i.e. April 26, 2020.

There is no other compensation or penalty payable, other than Royalty mentioned above.

Thanking you,

Yours faithfully, For UNICHEM LABORATORIES LIMITED

M. M. Shakere

NEEMA THAKORE Head – Legal & Company Secretary